title: Flow cytometry of transitional cell carcinoma of the urinary bladder: influence of prior local therapy.
abstract: A review of acridine-orange DNA and RNA flow cytometry (FCM) histograms of 249 bladder irrigation specimens from 129 patients with a previous history of transitional cell carcinoma (TCC) reveals that aneuploidy and tetraploidy (greater than 10% of total cell population) are reliable markers to detect the presence of bladder tumor in patients treated by surgical resection of tumor only. Tetraploidy is unreliable when the patient received intravesical chemotherapy or radiation therapy but aneuploidy remains accurate. A comparison of the reliability of FCM compared with cytology indicates an overall lower sensitivity and specificity for FCM (respectively, 52% and 73%) as opposed to cytology (respectively, 62% and 92%). Sensitivity is improved and raised to 77% if FCM and cytology are used in conjunction and reaches 82% in patients treated by surgery only and 88% in those who received radiation therapy. The lowest sensitivity and specificity obtained with FCM are in patients treated by intravesical chemotherapy (respectively, 44% and 58%) and the highest are in those treated by surgery without additional therapy (56% and 83%). This study demonstrates that FCM criteria for diagnosis of TCC of urinary bladder on bladder irrigation specimens depends on patient's treatment history. It also indicates that sensitivity and specificity of cytology to detect bladder tumor are superior to those obtained with FCM but both methods may be considerably improved if they are used in conjunction.
authors: Department of Pathology, University of Texas, M. D. Anderson Hospital and Tumor Institute, Houston.
authors: B
authors: B
authors: Têtu
authors: R L
authors: RL
authors: Katz
authors: S P
authors: SP
authors: Kalter
authors: A C
authors: AC
authors: Von Eschenbach
authors: B
authors: B
authors: Barlogie
mesh_terms: D000782:Aneuploidy; D014408:Biomarkers, Tumor / Q000235:genetics; D002295:Carcinoma, Transitional Cell / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000032:analysis; D004171:Diploidy; D005434:Flow Cytometry; D006801:Humans; D011123:Polyploidy; D012334:RNA, Neoplasm / Q000032:analysis; D007507:Therapeutic Irrigation; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm